OrbiMed Advisors RXST Position
Exited3-Fund ConvergenceOrbiMed Advisors exited their position in RxSight Inc. (RXST) in Q2 2023, after holding the stock for 2 quarters.
The position was first reported in Q1 2023 and has been tracked across 2 quarterly 13F filings.
RXST is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 12.9% of float with 6.3 days to cover, indicating significant bearish positioning against the stock.
About RxSight Inc.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Full company profile →Short Interest
12.9%
6.3 days to cover
OrbiMed Advisors RXST Position History
Frequently Asked Questions
Does OrbiMed Advisors own RXST?
No. OrbiMed Advisors exited their position in RxSight Inc. (RXST) in Q2 2023. They previously held the stock for 2 quarters.
How many hedge funds own RXST?
3 specialist biotech hedge funds currently hold RXST, including RA Capital Management, Driehaus Capital, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy RXST?
OrbiMed Advisors's position in RXST was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's RXST position increasing or decreasing?
OrbiMed Advisors completely exited their RXST position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
RXSTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →